Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel.

Abstract

Microtubule targeting agents (MTAs) are a mainstay in the treatment of a wide range of tumors. However, acquired resistance to chemotherapeutic drugs is a common mechanism of disease progression and a prognostic-determinant feature of malignant tumors. In prostate cancer (PC), resistance to MTAs such as the taxane Docetaxel dictates treatment failure as well as progression towards lethal stages of disease that are defined by a poor prognosis and high mortality rates. Though studied for decades, the array of mechanisms contributing to acquired resistance are not completely understood, and thus pose a significant limitation to the development of new therapeutic strategies that could benefit patients in these advanced stages of disease. In this protocol, we describe the generation of Docetaxel-resistant prostate cancer cell lines that mimic lethal features of late-stage prostate cancer, and therefore can be used to study the mechanisms by which acquired chemoresistance arises. Despite potential limitations intrinsic to a cell based model, such as the loss of resistance properties over time, the Docetaxel-resistant cell lines produced by this method have been successfully used in recent studies and offer the opportunity to advance our molecular understanding of acquired chemoresistance in lethal prostate cancer.

DOI: 10.3791/56327

Cite this paper

@article{Mohr2017GenerationOP, title={Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel.}, author={Lisa M. Mohr and Marc Carceles-Cordon and Jungreem Woo and Carlos Cordon-Cardo and Jos{\'e} M Domingo-Dom{\`e}nech and Ver{\'o}nica Rodriguez-Bravo}, journal={Journal of visualized experiments : JoVE}, year={2017}, volume={127} }